Long-term health sequelae and quality of life at least 6 months after infection with SARS-CoV-2: design and rationale of the COVIDOM-study as part of the NAPKON population-based cohort platform (POP)

PURPOSE: Over the course of COVID-19 pandemic, evidence has accumulated that SARS-CoV-2 infections may affect multiple organs and have serious clinical sequelae, but on-site clinical examinations with non-hospitalized samples are rare. We, therefore, aimed to systematically assess the long-term health status of samples of hospitalized and non-hospitalized SARS-CoV-2 infected individuals from three regions in Germany. METHODS: The present paper describes the COVIDOM-study within the population-based cohort platform (POP) which has been established under the auspices of the NAPKON infrastructure (German National Pandemic Cohort Network) of the national Network University Medicine (NUM). Comprehensive health assessments among SARS-CoV-2 infected individuals are conducted at least 6 months after the acute infection at the study sites Kiel, Würzburg and Berlin. Potential participants were identified and contacted via the local public health authorities, irrespective of the severity of the initial infection. A harmonized examination protocol has been implemented, consisting of detailed assessments of medical history, physical examinations, and the collection of multiple biosamples (e.g., serum, plasma, saliva, urine) for future analyses. In addition, patient-reported perception of the impact of local pandemic-related measures and infection on quality-of-life are obtained. RESULTS: As of July 2021, in total 6813 individuals infected in 2020 have been invited into the COVIDOM-study. Of these, about 36% wished to participate and 1295 have already been examined at least once. CONCLUSION: NAPKON-POP COVIDOM-study complements other Long COVID studies assessing the long-term consequences of an infection with SARS-CoV-2 by providing detailed health data of population-based samples, including individuals with various degrees of disease severity. TRIAL REGISTRATION: Registered at the German registry for clinical studies (DRKS00023742).

• Horn, A.
• Krist, L.
• Lieb, W.
• Montellano, F. A.
• Kohls, M.
• Haas, K.
• Gelbrich, G.
• Bolay-Gehrig, S. J.
• Morbach, C.
• Reese, J. P.
• Störk, S.
• Fricke, J.
• Zoller, T.
• Schmidt, S.
• Triller, P.
• Kretzler, L.
• Rönnefarth, M.
• Von Kalle, C.
• Willich, S. N.
• Kurth, F.
• Steinbeis, F.
• Witzenrath, M.
• Bahmer, T.
• Hermes, A.
• Krawczak, M.
• Reinke, L.
• Maetzler, C.
• Franzenburg, J.
• Enderle, J.
• Flinspach, A.
• Vehreschild, J.
• Schons, M.
• Illig, T.
• Anton, G.
• Ungethüm, K.
• Finkenberg, B. C.
• Gehrig, M. T.
• Savaskan, N.
• Heuschmann, P. U.
• Keil, T.
• Schreiber, S.